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Introduction
Pulmonary veno-occlusive disease (PVOD) is a rare and devastating cause of pulmonary hypertension (PH). PVOD is characterized by widespread fibrous intimal proliferation of septal veins and pre-septal venules, and is frequently associated with pulmonary capillary dilatation and proliferation 1 . Although the pathology firmly confirms PVOD, a non-invasive diagnostic approach is usually favored in these fragile patients in whom a lung biopsy carries a high risk of life-threatening complications. Decreased diffusing capacity of the lung for carbon monoxide, severe hypoxemia, radiological abnormalities on high-resolution CTs of the chest, and the occurrence of pulmonary edema after starting pulmonary vasodilator therapy strongly argue for PVOD 1, 2 . PVOD is a difficult form of PH to diagnose; it is frequently misclassified as idiopathic pulmonary arterial hypertension (PAH). Thus, the true incidence of PVOD is not known precisely, but is considered to represent 10% of cases of PAH that were initially considered as idiopathic or heritable, thus suggesting an incidence of less than 0.5/million/year 2, 3 .
The pathophysiological mechanisms of PVOD remain poorly understood, in particular because of the lack of animal models conducted on PVOD. PVOD may also be heritable and associated with biallelic mutations in the EIF2AK4 gene that codes for general control nonderepressible 2 protein (GCN2) 4 . Isolated case reports suggest that chemotherapeutic agents may induce the development of PVOD 5 . However, PVOD is usually reported in patients receiving multiple regimens of chemotherapy, making it difficult to individualize drugs or pathophysiological mechanisms.
We have recently published systematic analysis and the experience of the French PH network, which suggests that alkylating agents may represent the predominant chemotherapeutic class of drugs associated with PVOD 6 . The French PH network, which includes specialized PVOD 1, 2 . PVOD is a difficult form of PH to diagnose; it is frequently misclassifi ied ed ed a a as s s id id idio io iopa pa path th thic t pulmonary arterial hypertension (PAH). Thus, the true incidence of PVOD is not known prec cis is isel el ely, y, y, b b but ut ut is co co considered to represent 10% of f ca ca case es of PAH that were e e i i ini n n tially considered as d d dio o opathic or he e er ri rita abl bl le e, e t t thu hu hus s s su su sug gg gge e esti ti ting g g a an i i in n nci id i en nce e e of f f le le less s s t tha ha h n n 0. . .5/ 5/ 5/mi mi mil lli ion/ / /ye ye year ar 2,3 2,3 2,3 .
The pa pa pathop op ophys s sio ol o ogic ic cal al al m mec ec echa h h n n nis sm s s s s of f PV VO OD OD re e ema a ain n n po po poor r rly ly y und n nderst st stoo oo ood, i in n n p p par rtic c cular r r be be beca ca caus s use e e of of of t t the he he l l lac ac ack k k of of of a a ani ni nima ma mal l l mo mo mode de dels ls ls c c con on ondu d duc c cte te ted d d on on on P P PVO VO VOD D D. P P PVO VO VOD D D ma ma may al al also so so b b be e e he he heri ri rita ta tabl bl ble e e an an and d d 4 pulmonary vascular centers, has now facilitated a study on the trends of PH and has developed a pharmacovigilance program at national level [7] [8] [9] . Since 2012, any cases of severe PVOD that have occurred in the setting of anal cancer and after therapy with mitomycin-C (MMC) have been identified in the French PH registry and reported to the French pharmacovigilance agency. The present report summarizes the clinical characteristics and outcomes of seven cases of MMCassociated PVOD identified in the French Registry. To confirm a causal link between MMC and human PVOD, we demonstrated that in rats, MMC induced specific remodeling of pulmonary venous and capillary compartments, representing a unique animal model of human PVOD. We have also demonstrated a preventive effect of amifostine, a cytoprotective agent , in animal models 6 .
Methods

Patients
We prospectively collected the clinical, functional, and hemodynamic characteristics and outcomes of PVOD associated with MMC therapy from the French PH Registry. The Registry was established in accordance with the French bioethics laws (Commission Nationale de l'Informatique et des Libertés) and all patients gave their informed consent. Diagnosis of precapillary PH, defined as a mean pulmonary arterial pressure (mPAP) 25 mmHg with a normal pulmonary capillary wedge pressure (PCWP) of 15 mmHg, was confirmed in all patients by right heart catheterization. Right atrial pressure, mPAP, PCWP, and mixed venous oxygen saturation were recorded. Cardiac output (CO) was measured using the standard thermodilution technique. Pulmonary vascular resistance was calculated as (mPAP-PCWP)/CO, expressed in Woods unit. Acute vasodilator testing was performed during right heart catheterization using models 6 .
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Number of cycles of MMC therapy, associated chemotherapeutic agents, delay between the last dose of MMC and diagnosis of PVOD, and outcomes were collected.
In vivo study design
Rats Male and female Wistar rats (Janvier, eight weeks old) were subjected to different protocols to evaluate gender differences, dose-response relationships, and the kinetics of PH development after MMC exposure.
Protocol 1:
Gender-specific susceptibility. Male and female rats were randomly divided into saline (control, n=5) or MMC-exposed groups (Ametycin, Sanofi, 4 mg/kg, i.p., n=10). We performed hemodynamic measurements, assessed right-ventricle hypertrophy, and tissues were collected at 24 days after the injection.
Châtenay Malabry, France). Experiments were conducted according to the Europ pea ea ean n n Un Un Unio io ion n n Protocol 2: Dose-response relationships. Females, which harbored a more severe response to MMC (than males), were used to study MMC-induced pulmonary vasculopathy induced by fractioned lower doses. Rats were randomly divided into saline (control, n=5) or MMC-exposed groups: i.e., 2 and 3 mg/kg/week/2 weeks (i.p. n=10 for each dose). Rats were sacrificed at 30 days after the first injection. Hemodynamic measurements were made, right-ventricle hypertrophy was assessed, and tissue samples were collected.
Protocol 3: Kinetics of PH development. Female rats were randomly divided into saline (control, n=5) or MMC-exposed groups (3 mg/kg/week/2 weeks, i.p., n=10). We evaluated the hemodynamics using echocardiography at baseline, and at 1, 2, 3, 4, and 5 weeks after the first MMC injection (n=5-10 rats for each time point).
Protocol 4: Prevention study. Amifostine was given i.p. at 200mg/kg 30 min prior to 3 mg/kg/week/2 weeks of MMC (n=15). This group was compared to the MMC only-exposed group (MMC, 3 mg/kg/week/2 weeks, n=25). Survival was evaluated over five weeks. Survivors were sacrificed at five weeks after the second CP injection and assessed for hemodynamic, RVH measurements, and tissue collection. For information about the choice of MMC doses used in this study, see the online data supplement.
Hemodynamic measurements, evaluation of right-ventricle hypertrophy, and collection of tissues
Rats were anesthetized with isoflurane (2 L/min O 2 /3% isoflurane; Minerve, Esternay, France).
Hemodynamic measurements were recorded with a PowerLab 4/35 data-acquisition system and analyzed with LabChart software (AD-Instruments, Oxford, UK).
In anesthetized rats, blood from the ventral-tail artery was taken for serum analyses prior to the hemodynamic measurements. A 3.5-French umbilical-vessel catheter (Tyco, Plaisir, MMC injection (n=5-10 rats for each time point).
Protocol 4: Prevention study. Amifostine was given i.p. at 200mg/kg 30 min prior to 3 mg/k /k kg/ g/ g/we we week ek ek/2 /2 / w w wee ee eks of MMC (n=15). This group up up w w was compared to the e e M M MMC only-exposed g g grou u up (MMC, 3 3 3 m mg m /k /k /kg/ g/ g/we we week ek ek/2 /2 /2 w wee ee eeks ks ks, n=2 2 25) 5 5 . Sur rvi i ival l l w w was s s e e eva va valu lu luat at ated ed ed o o ove er fi fi ive ve ve w w wee ee eeks ks k . Su Su Surv rv rviv iv ivo o ors we we ere e e sacrifi ice ce ced a at a f five e e w we w ek ks s s af af afte t r th th the se e econ n nd CP in n njec c cti i ion o a a and nd nd a a ass s ses es sse s was inserted into the left carotid artery to allow measurement of CO by the thermodilution technique, after injection of cold saline into the pulmonary artery. Data on mean pulmonary artery pressure (mPAP) in mmHg, CO in mL/min, and total pulmonary resistances in Woods units were subject to statistical analyses.
Following exsanguination, the hilum of the left lung was ligated and the right lung was distended by infusion of formalin via the trachea, and then embedded in paraffin. The noninflated left lung was snap-frozen in liquid nitrogen and used for protein quantification. Fulton's index for right-ventricle hypertrophy, i.e., the ratio of right-ventricular weight divided by leftventricular (LV) plus septal weight (RV/LV+S), was calculated.
Quantification of pulmonary microvessel neomuscularization
Morphological assessment of pulmonary vascular remodeling is depicted in the online data supplement.
Hemodynamic evaluation by echocardiography
Rats were evaluated by transthoracic echocardiography (Vivid E9, GE Healthcare) using a highfrequency transducer (12 S-D 4-12MHz, GE Healthcare). Evaluation was performed under general anesthesia and spontaneous breathing (isoflurane induction 4% at room air plus isoflurane maintenance 2% at room air). Pulmonary-artery acceleration time 11 , CO, and RV dilatation assessed by the ratio between the RV and left ventricle and RV-wall thickness were Following exsanguination, the hilum of the left lung was ligated and the ri ri igh gh ght t t lu lu lung ng ng w w was as as distended by infusion of formalin via the trachea, and then embedded in paraffin. The nonnflat at ated ed ed l l lef ef eft t t lu lu lung g g w w was snap-frozen in liquid nitro oge ge gen n n and used for protei i in n n quantification. Fulton's n n nde e ex for righ ht--v v ven ntri ri ric c cle e e hy hy hype pe pert rt rtr ro roph ph phy y y, i. 
Histology and special stains
Hematoxylin-eosin, hematoxylin-eosin-safran, and orcein stains, and -smooth-muscle actin (clone 1A4, Sigma-Aldrich, Lyon, France) or proliferating cell-nuclear antigen (PCNA) (clone PC10, Dako, Les Ulis, France) immunohistochemical stains were applied to 5-μm-thick paraffinembedded lung sections or 10-μm frozen sections using a routine procedure.
Retrograde microbead injection from the left ventricle.
Following exsanguination, a catheter was introduced into the left ventricle via and tied to the aorta. Then polystyrene microbeads (10 μm diameter) (Polysciences, Warrington, USA), suspended in BSA 20% (Sigma Aldrich, St-Louis, USA), was injected into the left ventricle until the pulmonary veins became colored. The lungs were then inflated via the trachea with optimal cutting temperature compound diluted in PBS, and then frozen in dry-ice-cold isopentane, as previously described 13 .
Proliferation assay in vivo
To examine cell proliferation in rats, we visualized the incorporation of exogenously supplied 5-ethynyl-2'-deoxyuridine (EdU) to identify cells that underwent DNA replication. EdU was injected intraperitoneally into the rats at 5 μg/g, at 72 h before they were sacrificed. EdU staining was performed using a Click-iT® EdU Alexa Blots were incubated with horseradish peroxidase-conjugated goat anti-mouse diluted to 1:10,000 (Cell Signaling) or with horseradish peroxidase-conjugated goat anti-rabbit diluted to 1:5000 (Cell Signaling), respectively. Antibodies were revealed using enhanced chemiluminescence (ECL) (Perkin Elmer). ImageJ software (http://rsb.info.nih.gov/ij/) was used to quantify the level of protein expression.
Construction of network pathways
We used Ingenuity Pathway Analysis (IPA) (Qiagen, Redwood City, USA) as previously described 14 .
Statistical analyses
Comparisons were made using the Mann-Whitney (comparison between two groups) or
Kruskal-Wallis (comparison between more than two groups) test, followed by Dunn's test. To 1: :10 10 10,0 ,0 ,000 (Ce Ce Cell l l S Sig ig ignali i ing g g) or r w w wit it i h ho ho horser er erad a a is s sh pe p ro ox x xida a ase e e-c con on onju ju jug g gat te ted d d go o oa at an n nti i i-r --abbi bi bit t t dil lut t ted t t to 1: 1: 1:50 50 5000 00 00 ( ( (Ce Ce Cell ll ll S S Sig ig igna na nali li ling ng ng) ) ), r r res es espe pe pect ct ctiv i ivel el ely. A A Ant nt nti i ibo bo bodi di dies es es wer er ere e e re re reve e veal al aled ed ed usi si sing ng ng e e enh nh nhan an ance ce ced d d 10 compare the survival between the two groups, the log-rank test was used. P-values of <0.05 were considered to be statistically signi cant.
Results
Description of MMC-induced PVOD in the French PH Registry
We Table 1) .
At diagnosis, MMC-induced PVOD patients had severe clinical, functional, and hemodynamic symptoms. Patients were within NYHA functional class III (n=4) or IV (n=3).
Severe hypoxemia and a low diffusing capacity of the lung for carbon monoxide were observed in all patients ( Table 1) (Figure 1) . Pleural effusions were present in two of the seven patients but no cardiac effusions were observed. Genetic screening for EIF2AK4 and BMPR2 mutations was performed in four patients, and identified no mutations.
Due to the severely impaired hemodynamic parameters and the contraindication for lung transplantation, specific PAH therapies were introduced either as a monotherapy (n=2) or as a combination of endothelin-receptor antagonists and phosphodiesterase type-5 inhibitors (n=4) or prostacylins (n=1) ( Table 1) . Diuretics were initiated in all patients.
A fatal course of the disease was observed in four of the seven patients due to right-heart failure (n=2), local tumor progression (n=1), and severe pneumonia (n=1).
Estimated incidence of MMC-induced PVOD in patients with anal cancer in France
In cancer registries within France, the age-standardized incidence of squamous anal cancer is 0.2-0.7 per 100,000 cases per year in men, and 0.7-1.2 per 100,000 cases per year in women 15 .
Thus, we estimated that a maximum of 600 new cases of anal cancer are diagnosed each year in
France. In the French PH network, we diagnosed seven cases of MMC-induced PVOD in a 3-year period. The estimated incidence of PVOD in patients displaying anal cancer was 3.9/1000 patients/year and was higher than the incidence of PVOD in the general population, which is estimated at 0.5/million persons/year. The incidence of PVOD in the population that have anal cancer is, therefore, >5000 higher than in those with idiopathic PVOD. Indeed, not all patients that displayed anal cancer received MMC, which led to potential underestimation of the combination of endothelin-receptor antagonists and phosphodiesterase type-5 inhi hi hibi bi bito to tors rs rs ( ( (n n n=4 =4 =4) ) ) or prostacylins (n=1) ( Table 1) . Diuretics were initiated in all patients.
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MMC-induced pulmonary hypertension in rats with pulmonary vascular lesions resembling PVOD lesions
When male and female rats were injected with a single dose of 4 mg/kg MMC, they developed PH. This was evident at 24 days later by a significant increase in mPAP, a decrease in CO, increased total pulmonary vascular resistance, and compensatory right-ventricle hypertrophy, as quantified by the Fulton index (RV/(LV+S)) (Figure 2 ). Due to the small size of our experimental groups, we did not find a significant statistical difference between being male versus female using the log-rank test (data not shown). However, female rats seem to be more sensitive to the toxicity of MMC exposure as only a few (3/10) survived until the endpoint of the study (as compare to 8/10 males surviving).
Specific lesions of human PVOD include septal-vein and pre-septal-venule muscularization and fibrous occlusion; however, another important sign is focal capillary proliferation within the interstitium. Compared to the controls ( Figure 3A, B) , we observed severe pulmonary vascular remodeling in rats with MMC-induced PH; this included i) smoothmuscle cell hypertrophy/hyperplasia in pulmonary arteries ( Figure 3C) , ii) neomuscularization of the small distal and normally not muscularized pulmonary vessels (Figure 3D ), iii) vasculitis of the pulmonary arteries and veins ( Figure 3E ), iv) foci of pulmonary edema and capillaritis ( Figure 3F-G) , and v) foci of alveolar-wall thickening that resembled pulmonary capillary hemangiomatosis ( Figure 3H ).
Because female rats were more sensitive to MMC, we decided to treat females twice with lower doses (i.e., 2 and 3 mg/kg) of MMC, at one week apart. Rats exposed twice to MMC were versus female using the log-rank test (data not shown). However, female rats seem m m to to to b b be e e mo mo more re re ensitive to the toxicity of MMC exposure as only a few (3/10) survived until the endpoint of the tud dy y y (a (a (as s s co co comp m m ar r re e to 8/10 males surviving).
Specif fic c c l l les sio o on n ns o o of f f hu hu huma ma man n PV PV PVOD OD O inc c clu u ude s se ep pta a al-l-l-v v vein in in a and nd nd p p pre re re-s -s sep e e t tal-ve ve venu nu nule le le mu mu musc c cul u arizat at atio io i n an n nd fi fi ibr r rous o o occ cc cclusi si sio o on; ; ; h ho h we we wev v ver, a an n noth h he er er imp mp mpo ort rt r an an ant t si si s gn n n i is fo fo foca ca cal ca a api pi pillar ry pr pr prol ol olif if ifer er erat at atio io ion n n wi i with th thin in in t t the he he i i int nt nter er erst st stit it itiu i ium m m. C C Com om ompa pa pare re red d d to to to t t the he he c c con on ontr tr trol ol ols s s ( ( (Fi Fi Figu g gure re re 3A 3A 3A, B B B) ) ), we e e ob ob obse se serv r rved ed ed 13 too fragile to undergo invasive hemodynamic measurements, so we evaluated the severity of PH using the Fulton Index (Supplementary Figure 1) . At 30 days after the first injection, female rats exposed to 3 mg/kg MMC had severe PH when compared to controls and females given 2 mg/kg MMC. In animals that received 3 mg/kg MMC, we found severe obstructive lesions with pulmonary-artery adventitial and intimal thickening, and medial hypertrophy/hyperplasia (Figure 4A-D) . There was also intimal thickening and eosinophilic inflammation of pulmonary veins ( Figure 4E-H In In In con on ontras as ast t, t, m m mic icr rove e ess sels ls s ( ( (arte te ter ri iol o o e e es a and nd n v v ve enul ul les es es) ) ) pres es ese e ent in n n the co co cont nt ntro ro rol l l ra ra rats ts ts' ' ' pa pa pare re renc nc nchy h hyma ma ma wer er ere e e in in indi di dist st stin in ingu g guis is isha ha habl bl ble e e (b (b (bot ot oth h h we e were re re c c cha ha hara ra ract ct cte e eri ri rize e zed d d by b by e e ext t xtre re reme me mely l ly t t thi hi hin n n wa a wall ll ll lumens characteristic of veins and venules ( Figure 5A-C) . In MMC-exposed rats, the beads were plugged in severely remodeled microvessels, which we identified as post-capillary vessels
PVOD is characterized by numerous patch-like foci of capillary hemangiomatoses, which are produced by microvascular endothelial-cell proliferation (Figure 6B) , and was almost undetectable in the control rats' lung parenchyma ( Figure 6A ). To examine cell proliferation in rats, we visualized the incorporation of exogenously supplied EdU, to identify cells undergoing DNA replication. In control lung parenchyma, we observed very few EdU-positive cells ( Figure   6C ), whereas there was a foci of intense microvascular endothelial-cell proliferation (parenchymal CD34+EdU+ cells) in MMC-exposed rats (Figure 6C-G) . We also saw endothelial (luminal CD34+EdU+ cells) proliferation in pulmonary venules, which was identified by the presence of microbeads (retrograde injection) in the lumen ( Figure 6E) . We also observed adventitial-cell proliferation in the remodeled pulmonary microvessels of these animals ( Figure 6D, F) .
Kinetics of MMC-induced-pulmonary hypertension in rats
In order to assess the time course of PH development in MMC-exposed rats, we performed echocardiographic analyses at the time of MMC injection and then weekly for the five weeks.
Pulmonary-artery acceleration time was significantly reduced from the fourth week onwards susceptibility/development 16 . We measured the protein expression of these two genes in MMCexposed rats. We found that pulmonary protein level of BMPRII were unaffected in these animals, whereas protein levels of GCN2 were decreased ( Figure 7A) . Moreover, we found that GCN2 pulmonary protein levels were inversely related to the dose of MMC exposure: a high dose of MMC was related to higher PH and lower GCN2 levels ( Figure 7B) . Accordingly, explanted lungs from heritable PVOD, which we considered as 'pure' PVOD, showed null expression of GCN2, whereas BMPRII levels remained not statistically different from the control lungs ( Figure 7C) .
Although pulmonary protein level of BMPRII were unaffected in MMC-exposed rats and in human PVOD, both conditions were characterized by an almost total disruption of smad1/5/8 signaling ( Figure 7D and 7E) . Because the dysfunction of general control non-derepressible 2 (GCN2) signaling is crucial to the development of PVOD, we wondered if this pathway could modulate the smad cascade in the absence of BMPRII alteration, and thus explain, at least in part, our results. We used Ingenuity Pathway Analysis software (IPA), a web-based mammalian biology knowledgebase and analysis tool used for genomic data analysis, to decipher the exposed rats. We found that pulmonary protein level of BMPRII were unaffected d d in in in t t the he hese se se animals, whereas protein levels of GCN2 were decreased ( Figure 7A) . Moreover, we found that GCN2 N2 N2 p p pul ul ulmo mo monary ry ry p protein levels were inversely re re rela la lated to Amifostine prevented PVOD development when used in combination with MMC.
Amifostine ameliorated MMC-induced PVOD with notable improvement in survival ( Figure   8A ), right-ventricle hypertrophy (Figure 8B) , and pulmonary hemodynamics (increase in CO with a decrease in TPVR) in MMC + amifostine-treated rats (Figure 8C-E) . The decrease of TPR in CP + amifostine treated rats was linked to a decrease in resistive FM-distal microvessels,
and an increase in low-resistance NM distal microvessels (Figure 8F-H) . The percentage of occluded distal microvessels was significantly lowered in the amifostine group ( Figure 8I ).
Discussion
Since 2012, the French PH network has identified seven cases of PVOD in patients treated with MMC for squamous anal cancer, which is the major indication for MMC in France. These PVOD patients typically present with pre-capillary pulmonary hypertension, radiological abnormalities seen on high-resolution CTs of the chest, a low diffusing capacity of the lung for carbon monoxide (DLCO), and severe hypoxemia. These patients had severe symptoms and marked hemodynamic symptoms at diagnosis. According to previous reports, the prognosis of these PVOD patients appeared very poor, and four of the seven patients died shortly after diagnosis from acute right-heart failure and/or tumor progression [17] [18] [19] . Indeed, two of the seven patients received only MMC, which strongly reinforced the hypothesis of a direct link between MMC and PVOD. Nevertheless, these findings should not obscure the possibility that several other drugs may also have had similar effects as MMC. A recent published analysis of the association between chemotherapeutic agents and PVOD suggests that alkylating agents may
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In France, treatment with MMC is nearly exclusively used in the setting of anal cancer.
Therefore, we used the number of patients treated in France for this indication and extrapolated these results to obtain an incidence rate for PVOD after exposure to MMC. The lower estimated incidence of PVOD in patients displaying anal cancer is excessively high (3.9 per 1000/year) when compared to the incidence of PVOD in the general population (<1 per million/year).
However, MMC-induced PVOD has also been reported in the setting of non-small-cell lung cancer 18 , gastric adenocarcinoma 20 , and cervical carcinoma 5 . MMC lung toxicity is mainly caused by acute or chronic interstitial lung diseases, with an estimated incidence of 1.8% 21 .
In this study, we have confirmed the role of MMC in the development of pulmonary vascular lesions in animal models. In rats, MMC exposure induced pulmonary hypertension with pulmonary vascular lesions that resembled PVOD lesions: i.e., i) foci of alveolar-wall thickening suggestive of pulmonary capillary hemangiomatosis, ii) foci of pulmonary edema and capillaritis, iii) vasculitis of pulmonary veins and arteries, iv) intimal and adventitial remodeling of pulmonary arteries and veins (especially after two exposures to MMC), iv) neomuscularization of small distal pulmonary microvessels, v) venule obstruction, and vi) medial hypertrophy/hyperplasia of pulmonary arteries. The post-capillary nature of the pulmonary micro-lesions found in MMC-exposed animals was ascertained though retrograde injection of microbeads from the left ventricle into the venous bed of the lungs. Subsequently, the beads became plugged into severely remodeled microvessels of treated rats, and were identified as post-capillary vessels. MMC-exposed lungs also displayed foci of intense microvascular endothelial-cell proliferation, mimicking the patch-like foci of capillary hemangiomatosis found in PVOD. We also observed endothelial and adventitial cell proliferation in the remodeled
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We assessed the time course of PH development in MMC-exposed rats though echocardiographic analyses at the time of MMC injection, and then every week for four weeks.
Echocardiographic abnormalities appeared from the fourth week of follow-up. Females were more susceptible to MMC toxicity. Interestingly, while the female/male (F/M) ratio for anal cancer is 2/1 in the general population in France 15, 22 , the gender disequilibrium for MMCinduced PVOD was much stronger (F/M ratio: 6/1). Of note, the only man affected in our series was also HIV-infected, a risk factor for both PAH and anal cancer, whereas all six females were Interestingly, we demonstrated in animal models that MMC induced a PVOD-like disease and depletion of pulmonary GCN2 content in a dose-dependent manner. Although pulmonary protein level of BMPRII was unaffected in MMC-exposed rats and in human PVOD, both conditions were characterized by almost total disruption of smad1/5/8 signaling. Using IPA, we found a complex and unrevealed interplay between both signals, which improves our understanding of PH/PVOD pathobiology and justifies further investigations.
PVOD patients have a poor outcome, with a worse prognosis than PAH patients. To date, there is no cure for this devastating disease and the use of specific PAH therapies (prostacyclin, endothelin-receptor antagonists, or phosphodiesterase type 5 inhibitors) may induce lifetrategies, we evaluated the impact of amifostine in MMC-induced PVOD in rats. s. . I I In n n th th this is is a a ani ni nim m mal model, amifostine markedly improved survival, and significantly decreased pulmonary distal vasc c cul ul ular ar ar r r rem em emod o o el el elin in ing, total pulmonary resistance e, , , RV RV RV hypertrophy, and RV RV RV function. These ex ex exp pe p rimental dat at ata su u ug g gges es est t t th th that at at c c cyt yt ytop op pro o ote ectiv iv ive ag a en nt ts m m may ay ay h h hav av ave an an an a a ab bi bili li lit t ty to pr pr pre ev even en ent t t PV PV PVOD OD OD i i in n n pa a ati t t en en ents treat at ated e e w w wit th MM MM MMC.
In In Inte te tere re rest st stin in ingl gl gly, we e e de de demo mo mons ns nstr tr trat at ated ed ed i i in n n an an anim im imal al al mo mo mode de dels ls ls t t tha ha hat t t MM MM MMC C C in in indu d duce ce ced d d a a a PV PV PVOD OD OD l l -lik ik ike e e di di dise se seas as ase e e e threatening pulmonary edema 1, 2, 25, 26 MMC-related lung toxicity is a dose-dependent side effect 30 protein expression and may be damaged by MMC therapy, leading to specific pulmonary vascular toxicity 31 .
Development of lung damage induced by MMC begins with irregular thickening of the endothelial cells of the capillaries and progresses to the release of a surfactant and to the he main indication for this drug therapy 28 . Complications from this treatment are e e bo bo bone ne ne-m -m -mar ar arro ro row w w oxicity, renal damage, and interstitial lung diseases, caused by extensive tissue damage.
Pulm m mon on onar ar ary y y va va vascul ul ula a ar injuries, including alteration n ns s s to to to endothelial cells, h h hav av ave also been reported 29 .
M M MM M MC-related d lu lu lung ng n t tox ox oxic c cit it ity y y is s s t t t a a a do do dose se e-d -d -dep pende d d n n nt si ide e e ef f ffe fe fe t ct ct 30 30 30 d d d . It t w w was as as t t tho ho houg ght t t tha ha hat t t MM MM MMC C C co co coul ul uld d d ha a ave ve ve selecti ive ve ve to ox o i ic i ity y y o on o can an ance ce cer ce e ell l l s th th thr r ou u ugh gh gh spe eci ific c c t tu tumo mo mor r r ex ex e pr pr pres es ssi s s o o on of f MM MM MMC---ac ac activ vat t ting en en enzyme me mes s s, s s suc c uch h h as as as N N NAD AD AD(P (P (P)H )H )H:q :q :qui i uino no none ne ne o o oxi i xido do dore re redu d duct ct cta a a t t t se se se ( ( (NQ NQ NQO1 O1 O1) ) ). N N NQO QO QO1 1 1 is is is a a a f f fla la lavo o voen en enzyme me me t t tha ha hat t t activation of alveolar macrophages 32 . In a woman treated with MMC plus 5-FU, who developed progressive and fatal PH, scanning electron microscopy of the cast blood vessels showed distortion and destruction of alveolar capillaries that prohibited the passage of erythrocytes.
Extensive capillary damage and venous occlusion were observed, resulting in excessive new capillary formation, sometimes in angiomatoid configurations, and hypertrophy of pulmonary veins and arteries 33 . At the molecular level, it has been suggested that MMC-induced pulmonary vascular dysfunction may be related to its bifunctional alkylating property. Cultured pulmonaryartery endothelial cells exposed to MMC showed similar growth arrest and morphological alterations to monocrotaline pyrrole, another bifunctional alkylating substance known to be a potent trigger for experimental PH in rats 29, 34 . Both alkylating agents may compromise the capacity for replicative repair of endothelial cells, accounting for the delayed vascular injury induced by these molecules. Moreover, it has been shown that MMC results in a marked decrease in the biosynthesis of prostacyclin in cultured human umbilical-cord-vein endothelial cells 35 . Lastly, MMC has the characteristics expected of a bio-reductive alkylating agent:
activation of alkylating species occurs more readily under hypoxic conditions and the drug is selectively cytotoxic to hypoxic cells 36 . The underlying hypoxic condition may, thus, increase the pulmonary vascular side effects of MMC.
Biallelic mutations of the EIF2AK4 gene (coding GCN2) have been identified as the predisposing gene related to heritable PVOD 4 . According to our results, we can hypothesize that MMC depletes GCN2 in the lungs and mimics PVOD induced by EIF2AK4 mutations.
Interestingly, Wilson et al. have demonstrated that the loss of GCN2 promotes oxidative stress and in ammatory-mediated DNA damage during asparaginase therapy; this suggests that patients with reduced GCN2 may be at risk of developing hepatic complications during potent trigger for experimental PH in rats 29, 34 . Both alkylating agents may comprom om omis is ise e e th th the e e capacity for replicative repair of y endothelial cells, accounting for the delayed vascular injury f d ndu u uce ce ced d d by by by t t the h h se e e m m molecules. Moreover, it has bee ee een n n sh s own that MMC re e esul u u ts in a marked d de decr cr crease in th he b b bio osyn yn yn h th thes es esis is is o o of f f pr pr pros os osta ta t c c cyc clin n in n n cul ltu u ured d d hu hu huma ma man n n um um umbi bi bil li lica ca cal--cord rd d-v -v -vei ei ein n n en en e do do doth h hel el elia ia ial l l ce e ell l l s s s 35 . Last tly ly ly, MM MM MMC ha ha has the e e ch ch charac ac act te t r r rist st stics s s ex x xpe p c cte e ed o o of f f a b b bio o o-re re r du du duct t tiv i i e e e a alky y yla a ati t ng g g a a ag g gen nt:
ac ac acti ti tiva a vati ti tion on on o o of f f al al alky k kyla la lati ti ting ng ng s s spe pe peci ci cies es es o o occ cc ccur r urs s s mo mo more re re re re read ad adil il ily un n unde de der r r hy h hypo po poxi i xic c c co co cond nd ndit it itio io ions ns ns a a and nd nd t t the he he d d dru r rug g g is is is asparaginase treatment 37 . Our results may suggest that MMC-induced GCN2 depletion could favor similar oxidative and inflammatory pulmonary injuries.
Recently, Lathen et al. 38 demonstrated that the ERG-APLNR axis may play a role in the control of pulmonary-venule endothelial proliferation. These authors demonstrated that Erg binds to and serves as a transcriptional activator of the G-protein-coupled receptor gene, Aplnr,
and that the knockout of either Erg or Aplnr results in pulmonary venous-specific endothelial proliferation in vitro 38 . Indeed, mice with a homozygous deletion of Erg or Aplnr develop remodeled post-capillary pulmonary venules. Interestingly, in human PVOD lung tissues, levels of ERG protein, APLNR-mRNA, and protein were significantly decreased compared to control lungs 38 . Unlike our animal model of MMC-induced PVOD, which was characterized by a dosedependent depletion in pulmonary GCN2 content, the authors did not find any difference in the expression of GCN2 in lung tissues from animals with homozygous or heterozygous deletion of Due to the very severe PH, we we could only obtain h hem e odynamic data from on on ne e e female. Do Do D t t t pl pl plots s s wi wi with th th m m med ed edia ia ians ns ns; ***: P P P < < <0. 0 0 00 01, , , ****: *: *: P P P P P P <0. 0. 0.00 00 0001 01 01. P P P accompanying a terminal bronchiole with very thin muscular media. K,L, A small pu pu pulm lm lmon on onar ar ary y y ve ve vein with a typical thin loose, slack wall and a large lumen. M, A MMC-exposed small pulmonary artery ry ry a a acc cc ccom om ompa p p ny y yin in ing a terminal bronchiole with h h hyp yp ype ertrophied muscular r r m m media that is delimited by h h h h ap ap app pa parent interna a al l l an nd d d ex ex exte te tern rn rnal al al e e ela la last st stic ic ica. a O O, P P P, A A A MMC MC C-e e exp xp xpos os sed ed ed s sma m m ll ll ll p pul ul ulm mona a ary ry ry vei ei ein, n, n, typ yp yp c ic cal al ally ly ly de e eli l l m m mited by by y a a a sin n ng gl g e e e ela as a tica a a, , , w wi with s s se e eve e ere e e lume me men ob bs s stru u uct ct cti ion n n an n nd d d ex ex exte tens n n iv v ve e pe e eri ri r v v vascul ul ula a ar eo eo eosi si sino no noph ph phil il ilic ic ic i i inf nf nfla la lamm mm mmat at atio io ion n n. Q Q Q, R R R, S S S, M M MMC MC MC e e -exp p xpos os osed ed ed a a art rt rter er erio io iole le le ( ( (R R R) ) ) an an and d d ve e venu n nule le le ( ( (S S S) ) ) ar ar arra ra rang ng nged ed ed i i in n n lu l lung ng ng Co Co Cont nt ntro ro rol l l hu h huma ma man n n lu l lung ng ng p p par ar aren en ench ch chym m yma a a di di disp sp spla la lays s ys ver er ery fe fe few ce ce cell ll llul l ular ar ar p p pro ro roli li life fe fera ra rati ti tion on on. B B B, P P Pul l ulmo mo mona na nary r ry c c cap ap apil il illa la lary ry ry y 
